Brief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
BRIEF-Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis Sept 29 (Reuters) - Cartesian Therapeutics, Inc. RNAC.O:
CARTESIAN THERAPEUTICS ANNOUNCES ADDITIONAL RETREATMENT DATA FOR DESCARTES-08 HIGHLIGHTING DEEP AND DURABLE RESPONSES IN PATIENTS WITH MYASTHENIA GRAVIS
CARTESIAN THERAPEUTICS, - DESCARTES-08 SHOWS MEAN MG-ADL REDUCTION OF 6.6 POINTS AT MONTH 12 POST RETREATMENT
CARTESIAN THERAPEUTICS, - MEDIAN INTERVAL BETWEEN INITIAL TREATMENT AND RETREATMENT INFUSION IS 16.6 MONTHS
CARTESIAN THERAPEUTICS, - TOPLINE DATA FROM PHASE 3 AURORA TRIAL EXPECTED IN 1Q27
CARTESIAN THERAPEUTICS, - NO NEW SAFETY SIGNALS REPORTED; SAFETY PROFILE CONSISTENT WITH PREVIOUS DATA
CARTESIAN THERAPEUTICS, INC.: BLA FILING EXPECTED IN MID-2027
Source text: ID:nGNX4338cr
Further company coverage: RNAC.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview